Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORASURE TECHNOLOGIES INCOSUR · Entity 6152 | Director | May 21, 2019 | May 22, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORASURE TECHNOLOGIES INC
Report date May 21, 2019 · Filed May 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,865 |
Reported balance
After 2019-05-21 transaction · row 1
1 source rowRow 1 · 2019-05-21 · Grant · Acquired 12,382 · Balance 16,865 F1: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on May 15, 2020. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on May 15, 2020. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 120,253 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2021 Filed Jul 23, 2021 16:52 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerCommon Stock, par value $.0001 per share | 120,253 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000076 · wf-form4_162707353258876.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 16:54 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 29,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000057 · wf-form4_162646885634570.xml · nonDerivative · entry 2 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,253 F2 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 16:54 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 26,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000057 · wf-form4_162646885634570.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,752 F1 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 17:52 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 24,473 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000024 · wf-form4_161472555263241.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,940 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:04 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 2,510 | $157.96 | $396,479.60 |
DisclosureSEC source: 0000899866-20-000092 · wf-form4_160832903829817.xml · nonDerivative · entry 3 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,467 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:04 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 6,853 | $157.96 | $1,082,499.88 |
DisclosureSEC source: 0000899866-20-000092 · wf-form4_160832903829817.xml · nonDerivative · entry 2 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,977 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:04 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 15,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000092 · wf-form4_160832903829817.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,830 F1 · shares: Shares acquired on vesting of Performance Stock Units previously granted on February 28, 2018 under the 2017 Stock Incentive Plan. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 17:17 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,298 | $124.00 | $160,952.00 |
DisclosureSEC source: 0000899866-20-000089 · wf-form4_160686101427825.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,459 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 18:20 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 883 | $90.54 | $79,946.82 |
DisclosureSEC source: 0000899866-20-000020 · wf-form4_158327759431214.xml · nonDerivative · entry 2 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,757 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:20 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 10,880 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000020 · wf-form4_158327759431214.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,640 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 18:36 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 5,441 | $113.20 | $615,921.20 |
DisclosureSEC source: 0000899866-19-000103 · wf-form4_157550259239392.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,760 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $113.20 - $114.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 16:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 578 | $132.00 | $76,296.00 |
DisclosureSEC source: 0000899866-19-000078 · wf-form4_156140911872892.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Chief Strategy & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,201 F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:33 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon Stock | 12,382 | $8.48 | $104,999.36 |
DisclosureSEC source: 0001593968-19-001162 · primary_01.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,865 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on May 15, 2020. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| May 06, 2019 Filed May 7, 2019 20:19 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | Tax withholdingCommon Stock | 1,661 | $9.88 | $16,414.83 |
DisclosureSEC source: 0001593968-19-001055 · primary_01.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,483 F1 · kind: Withholding of shares to pay the tax liability associated with vesting of restricted shares Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 267 | $132.92 | $35,489.64 |
DisclosureSEC source: 0000899866-19-000043 · wf-form4_155173954522827.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Chief Strategy & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,529 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $134.75. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 20:23 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000051 · wf-form4_155183538033538.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Chief Strategy & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,779 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:30 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantCommon stock | 6,144 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209784-18-000022 · edgar.xml · nonDerivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,144 F1 · kind: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on May 6, 2019. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. F1 · price: Grant of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, cliff vesting on May 6, 2019. Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:29 UTC | ORASURE TECHNOLOGIES INC OSUR · Entity 6152 | GrantNon-qualified stock options · Derivative | 40,000 | $0.00 Strike: $21.89 | $0.00 |
DisclosureSEC source: 0001209784-18-000003 · edgar.xml · derivative · entry 1 SARIN ARADHANA · CIK 0001729110 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-01-31 F1 · kind: Grant of nonqualified stock options, vesting and exercisable on a monthly basis, over the 24 months immediately following the grant date. Vesting shall cease immediately if the named individual ceases to serve as a member of the Board of Directors. F1 · derivative.exercise_date: Grant of nonqualified stock options, vesting and exercisable on a monthly basis, over the 24 months immediately following the grant date. Vesting shall cease immediately if the named individual ceases to serve as a member of the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.